Rapamycin and the Future of Aging Research

Rapamycin has been sitting in plain sight for over 25 years. It's FDA-approved, it's off-patent, and millions of dollars of human safety data already exist. It was developed for organ transplants, not aging and that's actually the problem. No pharmaceutical company has financial incentive to fund the large human trials needed to prove what the lab data already suggests. The one major trial now underway exists only because a single donor decided to pay for it himself. To hear how rapamycin can impact the future of again, visit: https://podcasts.apple.com/us/podcast/critically-speaking/id1463016517 Visit Critically Speaking on Social Media! Twitter: https://x.com/critispeakpod Facebook: https://www.facebook.com/criticallyspeakingpodcast/ Instagram: https://www.instagram.com/criticallyspeakingpodcast/ BlueSky: https://bsky.app/profile/criticallyspeaking.bsky.social #rapamycin #mTOR #longevityscience